Curiteva achieved record revenue for 3Q20, and announced the successful launch of their Prodigy Open and MIS posterior fixation systems. The company reported six consecutive quarters of revenue growth since the launch of their first product in January 2019, and currently has over 200 surgical kits in circulation throughout the U.S.
The release of the Prodigy posterior fixation systems complements a portfolio that includes PLIF, TLIF, ALIF and ACDF interbody and fixation systems developed in-house since 2017. Additional announcements are slated to release by the end of 2020.
“Our shared vision is to build a strong portfolio of innovative products in support of existing customer requirements as we invest tirelessly in the development or acquisition of novel technologies to advance patient outcomes and increase our value proposition,” said CEO Mike English.
“Our experience and expertise in designing and building precision implants and instruments allowed us to dedicate resources and equipment to support our contract customers and ensure we remained fully operational through this challenging time,” said Bill Voss, Chief Operating Officer.
Curiteva achieved record revenue for 3Q20, and announced the successful launch of their Prodigy Open and MIS posterior fixation systems. The company reported six consecutive quarters of revenue growth since the launch of their first product in January 2019, and currently has over 200 surgical kits in circulation throughout the U.S.
The...
Curiteva achieved record revenue for 3Q20, and announced the successful launch of their Prodigy Open and MIS posterior fixation systems. The company reported six consecutive quarters of revenue growth since the launch of their first product in January 2019, and currently has over 200 surgical kits in circulation throughout the U.S.
The release of the Prodigy posterior fixation systems complements a portfolio that includes PLIF, TLIF, ALIF and ACDF interbody and fixation systems developed in-house since 2017. Additional announcements are slated to release by the end of 2020.
“Our shared vision is to build a strong portfolio of innovative products in support of existing customer requirements as we invest tirelessly in the development or acquisition of novel technologies to advance patient outcomes and increase our value proposition,” said CEO Mike English.
“Our experience and expertise in designing and building precision implants and instruments allowed us to dedicate resources and equipment to support our contract customers and ensure we remained fully operational through this challenging time,” said Bill Voss, Chief Operating Officer.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
